Recursion Pharmaceuticals Inc
RXRX5.030USD
-0.370-6.85%
Fechamento 06/27, 16:00（ET）Cotações atrasadas em 15 min
2.04BValor de mercado
PerdaP/L TTM
Mais detalhes de Recursion Pharmaceuticals Inc Empresa
Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology include REC-617, REC-1245, REC-3565 and REC-4539. Its clinical programs in rare diseases include REC-994, REC-4881, REC-2282, and REC-3964. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors.
Informações da empresa
Código da empresaRXRX
Nome da EmpresaRecursion Pharmaceuticals Inc
Data de listagemApr 16, 2021
Fundado em2013
CEODr. Christopher Gibson, Ph.D.
Número de funcionários840
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 16
Endereço41S Rio Grande Street
CidadeSALT LAKE CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal84101
Telefone13852690203
Sitehttps://www.recursion.com/
Código da empresaRXRX
Data de listagemApr 16, 2021
Fundado em2013
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 28 de mai
Atualizado em: qua, 28 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
Investidores
Investidores
Proporção
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
Tipos de investidores
Investidores
Proporção
Investment Advisor
36.58%
Investment Advisor/Hedge Fund
19.62%
Venture Capital
8.74%
Sovereign Wealth Fund
4.12%
Individual Investor
3.17%
Research Firm
2.16%
Hedge Fund
2.01%
Corporation
1.93%
Bank and Trust
0.86%
Other
20.83%
Participação acionária institucional
Atualizado em: ter, 4 de mar
Atualizado em: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
637
324.02M
81.93%
+29.39M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
2022Q4
321
167.85M
92.66%
-946.19K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
ARK Investment Management LLC
32.35M
8.19%
-422.79K
-1.29%
Dec 31, 2024
The Vanguard Group, Inc.
33.97M
8.6%
+9.74M
+40.18%
Dec 31, 2024
Baillie Gifford & Co.
24.86M
6.29%
-375.81K
-1.49%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.31M
5.14%
+2.56M
+14.39%
Dec 31, 2024
SB Global Advisers Ltd
14.67M
3.71%
+14.67M
--
Dec 31, 2024
Kinnevik AB
11.91M
3.01%
--
--
Dec 31, 2024
State Street Global Advisors (US)
12.58M
3.18%
-291.91K
-2.27%
Dec 31, 2024
Mubadala Investment Company PJSC
12.99M
3.29%
--
--
Dec 31, 2024
DCVC Management Co, LLC
5.94M
1.5%
-3.73M
-38.55%
Dec 31, 2024
Novo Holdings A/S
10.11M
2.56%
+10.11M
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
ARK Genomic Revolution ETF
4.95%
ARK Innovation ETF
1.5%
First Trust Nasdaq AI and Robotics ETF
1.01%
AXS Green Alpha ETF
0.81%
Franklin Genomic Advancements ETF
0.66%
WisdomTree BioRevolution Fund
0.64%
Main Thematic Innovation ETF
0.59%
SPDR S&P Biotech ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.37%
Ver Mais
ARK Genomic Revolution ETF
Proporção4.95%
ARK Innovation ETF
Proporção1.5%
First Trust Nasdaq AI and Robotics ETF
Proporção1.01%
AXS Green Alpha ETF
Proporção0.81%
Franklin Genomic Advancements ETF
Proporção0.66%
WisdomTree BioRevolution Fund
Proporção0.64%
Main Thematic Innovation ETF
Proporção0.59%
SPDR S&P Biotech ETF
Proporção0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.45%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.37%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
